Physician profile
Alexis Euart
NPI 1831761204
$7,572.19
in general payments reported to CMS, 2019-2025
30 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what 88% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $113 · 2022: $3,005 · 2023: $1,848 · 2024: $1,582 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,303 · Education: $94.99 · Debt Forgiveness: $55.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,303.45 |
| Education | $94.99 |
| Debt Forgiveness | $55.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,431.34 | 2021-2025 | Linq II, Micra, Symplicity G3 |
| Itamar Medical INC | $1,037.84 | 2021-2024 | Watchpatone |
| Merck Sharp & Dohme LLC | $820.48 | 2022-2025 | Verquvo, Capvaxive |
| Heartflow, INC. | $700.56 | 2022-2025 | Ffrct |
| Novartis Pharmaceuticals Corporation | $556.54 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $410.34 | 2022-2024 | Uptravi, Opsumit |
| Pfizer INC. | $403.57 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $301.39 | 2022-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $252.06 | 2022-2023 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.67 | 2022-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $222.48 | 2021-2023 | Xarelto |
| Inspire Medical Systems, INC. | $164.93 | 2024-2025 | Inspire |
| Boston Scientific Corporation | $155.43 | 2022-2025 | Wavewriter Alpha Prime 16, Watchman Flx |
| Atricure, INC. | $148.47 | 2024 | |
| Esperion Therapeutics, INC. | $110.83 | 2021-2024 | Nexletol |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $79.19 | 2023-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $69.39 | 2022 | |
| Baxter Healthcare | $55.76 | 2023 | |
| Amgen INC. | $52.57 | 2021-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $50.72 | 2022-2023 | Brilinta |
| Biosense Webster, INC. | $44.19 | 2023 | Carto 3 |
| Novo Nordisk INC | $39.47 | 2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $38.68 | 2025 | Zepbound, Mounjaro |
| Bridgebio Pharma, INC. | $33.32 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $32.22 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $29.45 | 2023 | |
| Daiichi Sankyo INC. | $28.00 | 2023 | Injectafer |
| Medicomp INC | $22.49 | 2023 | Telepatch Cardiac Monitor |
| Azurity Pharmaceuticals, INC. | $16.06 | 2025 | Edarbi |
| Cvrx, INC. | $14.75 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Euart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.